Gilead Sciences Inc. may be experiencing a slowdown in therapy starts in hepatitis C, with some analysts predicting a bit of erosion in its dominant market share, but competitors Merck & Co. Inc., AbbVie Inc. and Bristol-Myers Squibb Co. still would love to have Gilead's problems.
Gilead Faces Challenges In HCV, But Competitors Would Switch Places
Gilead Sciences Inc. may be experiencing a slowdown in therapy starts in hepatitis C, with some analysts predicting a bit of erosion in its dominant market share, but competitors Merck & Co. Inc., AbbVie Inc. and Bristol-Myers Squibb Co. still would love to have Gilead's problems.
More from Immunological
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
More from Therapy Areas
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.